GLP-1 South Africa · Community
Evidence-based, patient-first information on semaglutide, tirzepatide, and the GLP-1 medications changing how we treat weight-related conditions and type 2 diabetes.
No hype. No sales. Just the facts — and the questions worth asking.
ABOUT GLP-1 SA
GLP-1 SA exists because the conversation about GLP-1 medications in South Africa has been dominated by hype, misinformation and content that serves commercial interests rather than patients. We are an independent, editorially driven information platform with a single purpose: to help South Africans make better-informed decisions about GLP-1 treatment.
Every article is either evidence-based, sourced from peer-reviewed research or reviewed by qualified health professionals.
✓ Independent — no product sales, no conflicts of interest
✓ Evidence-based — most claims are sourced to peer-reviewed research or credible clinical data
✓ SA-specific — focused on access, cost, regulation and patient experience in South Africa
Our positioning
“We say what the science says — even when that’s uncomfortable, contested or incomplete.”
GLP-1 treatment is one of the most significant developments in medicine in a generation. It is also one of the most commercially influential. Patients in South Africa need access to information that respects their ability to engage with nuance, complexity and evolving evidence.
We cover the controversial because the controversial is where the most important decisions are made. We cover the science because without it, the controversy has no anchor.
We cover both the science and the debate. We examine controversial topics because they often shape the decisions patients and clinicians face. We anchor our reporting in the best available evidence, while acknowledging where uncertainty remains.
Latest news
South Africa’s pharmaceutical manufacturers are pressing law enforcement to act against the open sale of unregistered weight-loss medicines, warning that inaction is undermining both patient safety and investor confidence in the country’s regulatory system. “Slam-dunk cases” sitting unprosecuted Stavros Nicolaou, chair of the Pharmaceutical Task Group (PTG) and a senior executive at Aspen Pharmacare, says…
South Africa’s two main medicines regulators are revising the rules that govern how pharmacies may customise, or “compound,” medicines — including copycat versions of GLP-1 drugs such as Ozempic, Wegovy and Mounjaro — after warning…
Discovery Vitality has broadened its HealthyWeight programme to include doctor-led clinical assessments and, where appropriate, prescriptions for GLP-1 anti-obesity medicines, as the insurer responds to a near-tripling in member claims for drugs such as Wegovy,…
Danish pharmaceutical giant Novo Nordisk, the maker of Ozempic and Wegovy, has announced it will shorten its public-facing brand to simply “Novo” as part of a broader corporate culture overhaul, alongside a new slogan, “Lasting…
The long-running legal battle between Novo Nordisk and South African compounding pharmacy iDexis has taken another turn, after a Pretoria High Court judge refused the pharmacy’s bid to appeal an interim order that bars it…
Aspen Pharmacare, Eli Lilly’s exclusive distributor for Mounjaro across sub-Saharan Africa, says it expects the weight-loss and diabetes drug to generate more than R2 billion (about $124 million) in sales for its 2027 financial year.…
Despite the clinical promise of GLP-1 receptor agonists such as semaglutide and tirzepatide, at least one South African healthcare leader is cautioning that the drugs cannot, on their own, fix the country’s deepening diabetes crisis.…
Content library
Free articles are open to everyone. Register to unlock the full library — including
side effect tracking, real patient journeys and mental health coverage.
Somewhere in the deserts of the American Southwest and northern Mexico lives a slow-moving, black-and-orange lizard with a bite you don’t forget.…
Compounding is a century-old pharmacy practice that became a multi-billion dollar flashpoint when GLP-1 medications went into shortage. Here is what it…
Tirzepatide reduced sleep apnoea severity by up to 63% in the SURMOUNT-OSA trial — a result comparable in magnitude to CPAP therapy.…
Not everyone who stops GLP-1 therapy does so because of cost or side effects. Lerato stopped because she felt ready. She shares…
Thabo started semaglutide for weight management alongside type 2 diabetes. He hit a six-week plateau in month 3. Here is what happened…
Practical pathways, honest tradeoffs and the questions worth asking your scheme — from a South African perspective.
The evidence gap, honestly described. What the current data shows about GLP-1 exposure in early pregnancy — and the specific guidance that…
The plateau explained properly — including the part about metabolic adaptation that most prescribers do not take time to explain.
Practical guidance, not a disclaimer. What actually happens to the medication in your system, and the specific steps to take depending on…
The answer and the nuance behind it — from what the interaction actually involves, to the surprising finding that GLP-1s may reduce…
GLP-1 receptors are found throughout the brain. Preclinical evidence for neuroprotection is striking. Epidemiological signals are encouraging. The definitive trials are still…
PCOS affects roughly 10% of women of reproductive age and has significant metabolic overlap with the conditions GLP-1s treat well. Off-label prescribing…
A 20% reduction in major cardiovascular events. Over 17,000 patients. Without any diabetes. The SELECT trial may be the most important GLP-1…
Weight loss plateaus on semaglutide typically occur around week 60 in trials. In real practice, many patients experience them much earlier. The…
The honest answer involves the biology of obesity, the STEP 1 extension data, and an important distinction between "needing to" and "choosing…
Losing 15–20% of your body weight changes how you look, how others treat you, and — in ways harder to predict —…
A 2025 JAMA Psychiatry RCT confirmed semaglutide significantly reduces alcohol consumption in people with alcohol use disorder. A Swedish cohort of 227,000…
Patients describe a reduction in food obsession, anxiety and intrusive thoughts that goes beyond appetite suppression. The mechanism is real. The implications…
The landmark semaglutide trials included "lifestyle counselling" as a standard component. What that actually meant — and what structured exercise would have…
Fatigue is commonly reported in the first months. Understanding the mechanism — and the timeline — helps patients build realistic expectations for…
Most people on GLP-1s are losing weight. Many are also losing muscle. The STEP trials did not require resistance training. That omission…
Many patients report reduced alcohol cravings. Others find that alcohol hits harder and faster than before. Both responses are real — and…
Fatty food, carbonated drinks and large portions are the consistent triggers. The foods that help are more individual — but there are…
When appetite drops dramatically, protein is typically the first casualty. Here is why it should be the last, and how to hit…
Some South Africans are sourcing compounded or "research grade" semaglutide online. Here is an honest assessment of what that means legally, medically…
Global demand has outpaced manufacturing capacity since 2022. Understanding why — and what manufacturers are doing about it — matters for every…
Private prescription, medical aid, out-of-pocket cash, and the growing grey market. What getting onto GLP-1 treatment actually looks like in South Africa…
Patients report hair loss on semaglutide with enough consistency that it demands a proper answer. The evidence suggests the drug is not…
Nausea affects up to 44% of patients on semaglutide. For most it peaks in weeks 2–4 and diminishes by week 8. But…
You can lose 15% of your body weight on semaglutide. But a significant proportion of that loss may be muscle, not fat.…
The STEP trials are among the most cited studies in modern medicine. Here is what they measured, what they did not, and…
In the STEP 1 trial, the top responders lost nearly 25% of body weight. The bottom 25% lost less than 5%. The…
They all target GLP-1 receptors. But the mechanisms, results and side effect profiles diverge in ways that matter enormously for individual patients.
We're tracking five South African patients on GLP-1 therapy — with their permission and their unfiltered words — over the next twelve…
Heart disease. Kidney disease. Sleep apnoea. Even Alzheimer's. The indications pipeline is expanding fast — and most patients don't know it.
A reduced appetite sounds like the simple part. It isn't. Here is what dietitians say about eating well on a dramatically smaller…
Two-thirds of weight regained within a year, according to the trials. But real-world data tells a more complicated — and more encouraging…
Your gut has been signalling to your brain for millions of years. GLP-1 medications borrowed that pathway — and the results have…
Register free to read every article, receive our weekly digest and ask our expert panel.
Already registered?
Site access
GLP-1 SA is free at its core. Register for full access to every article.
✓ The science, plain and simple
✓ Nutrition alongside GLP-1s
✓ GLP-1s beyond obesity
✓ “Stopped after 6 months”
— Side effect tracker
— Real patient journeys
— Mental health dimension
— Access & cost in SA
✓ Everything in visitor access
✓ Side effect tracker — reports
✓ Patient journeys, unfiltered
✓ Mental health: the hidden dimension
✓ SA-specific access & cost guide
✓ Exercise guide: muscle & GLP-1s
✓ Shortage alerts for SA
Daily Updates, New Research, SA Access Updates, and Patient Insights.
Medical disclaimer: GLP1SA.com provides general information only. Nothing on this site constitutes medical advice. Always consult a qualified healthcare professional before starting, stopping or changing any treatment. GLP-1 medications are prescription-only medicines in South Africa. Information is reviewed for accuracy but individual circumstances vary significantly.
Register free to read every article, receive our weekly digest and submit questions to our expert panel.
Already registered? Sign in here
